Amortization expense was approximately $46 for both the three months ended June 30, 2018 and June 30, 2017, respectively, and approximately $93 for both the six months ended June 30, 2018 and June 30, 2017, respectively.
During the third quarter of 2017, we revised the June 2016 Plan.
Our effective income tax rate was 37.7% and 28.4% in the second quarters of 2018 and 2017, respectively.
Generally, these RSUs vest over a three-year period.
During the three and six months ended June 30, 2018, we recognized a decrease of revenues of $46 and an increase in revenues of $86, respectively, that were included in contract liabilities at the beginning of the period.
The increase in the effective tax rate for the six months ended June 30, 2018, compared with the same period in 2017, was primarily attributed to tax expense of $1,703 related to a one-time cash distribution from Taiwan, offset by the previously mentioned statutory tax rate reduction resulting from the Tax Act.
for the six-month periods ended June 30, 2018 and 2017, since the revenue target was not deemed likely to be attained based on our current forecast.
Our effective income tax rate was 30.2% and 29.4% in the first half of 2018 and 2017, respectively.
Transaction losses for the three and six months ended June 30, 2018 were $2,194 and $918, respectively and transaction gains for the three and six months ended June 30, 2017 were $1,162 and $1,557, respectively, which have been included in other income (expense) in the Condensed Consolidated Statement of Earnings.
For these computations, we have recorded an estimate in our effective tax rate for the three-months ended June 30, 2018.Gross margin as a percent of sales was 35.4% in the second quarter of 2018 compared to 33.9% in the second quarter of 2017.
Research and development expenses were $12,983 or 5.6% of sales in the six months ended June 30, 2018 compared to $12,052 or 5.9% of sales in the comparable prior year period.
Gross margin as a percent of sales was 34.7% in the first half of 2018 compared to 34.0% in the first half of 2017.
Research and development expenses were $6,476 or 5.5% of sales in the second quarter of 2018 compared to $6,049 or 5.7% of sales in the comparable quarter of 2017.
Sales were $231,551 in the six months ended June 30, 2018, an increase of $25,711 or 12.5% from the six months ended June 30, 2017.
Sales were $118,021 in the second quarter of 2018, an increase of $12,335 or 11.7% from the second quarter of 2017.
The Noliac acquisition, which was completed in May 2017, added $2,508 in sales in the second quarter of 2018 and $1,543 in the second quarter of 2017.
Other sales increased $12,614 or 17.8%.